A Study of Laropiprant (MK-0524) in Participants With Moderate to Severe Erythematotelangiectatic Rosacea (MK-0524-155)
Status:
Completed
Trial end date:
2012-04-01
Target enrollment:
Participant gender:
Summary
This study will assess the effect of MK-0524 relative to placebo, on signs and symptoms of
rosacea and to determine the safety and tolerability profile of MK-0524 in participants with
rosacea.